Uncategorized

EyePoint plummets on pivotal data for main drug

Though its drug missed the main goal of a wet AMD study, EyePoint, as well as analysts, still see a path toward approval. Investors may be harder to win over, however.

​Read More

Published

on

Though its drug missed the main goal of a wet AMD study, EyePoint, as well as analysts, still see a path toward approval. Investors may be harder to win over, however.

​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version